Choose Language
Select a language for news translation.
Eli Lilly (Symbol: LLY) options are showing a volume of 20,775 contracts thus far today. That number of contracts represents approximately 2.1 million underlyi…
Eli Lilly and Company (NYSE: LLY ) is among the stocks with the best earnings growth for the next 3 years . On June 15, Eli Lilly and Company (NYSE:LLY) shared…
Written by Prosper Junior Bakiny for The Motley Fool -> Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent …
With a profit margin of 34.99% and net income of $20.64 billion (FY25), Eli Lilly and Company (NYSE: LLY ) ranks among the most profitable blue chip stocks to …
Jordi Visser argues Eli Lilly's AI infrastructure, proprietary metabolic data, and GLP-1 drugs could make it the world's largest company within 5 years. Lilly…
Written by Joe Tenebruso for The Motley Fool -> Investors are excited about retatrutide's potential. Rival drugmakers are finding it difficult to keep pace w…
Written by Reuben Gregg Brewer for The Motley Fool -> Eli Lilly is probably best known for its dominant GLP-1 drugs right now. The company's recent $3.8 bill…
Two drugs make up nearly two-thirds of Eli Lilly 's (NYSE: LLY) top line, generating around $12.8 billion in revenues in the first quarter of 2026. The two dru…
Written by Jeff Siegel for The Motley Fool -> Eli Lilly now controls roughly 60% of the GLP-1 market. International growth could become Lilly's next major ca…
Written by Reuben Gregg Brewer for The Motley Fool -> Wall Street likes stories, and a big one today is the huge demand for GLP-1 weight-loss drugs. Novo Nor…
Written by Prosper Junior Bakiny for The Motley Fool -> Eli Lilly has worked hard to diversify its pipeline. Three new acquisitions will further help decreas…
